Affiliation:
1. Department of Neurology, Renji Hospital, School of Medicine Shanghai Jiaotong University, 160 Pujian Rd, Shanghai 200127, P. R. China
Abstract
Background:
Neural stem/progenitor cells (NSPCs) transplantation has been recognized in
recent years as an effective strategy for the treatment of ischemic stroke. Several preclinical studies have
demonstrated the feasibility, safety, and efficacy of NSPCs therapy.
Method:
We conducted a systematic review of the published literature in Pubmed reporting the use of
NSPCs in preclinical studies between 2010 and 2021. Based on the articles reporting data, the key factors
affecting efficacy were listed.
Results:
A total of 71 preclinical studies, including 91 treatment arms, were identified. The results
showed that several factors could influence the outcomes of NSPCs transplantation, including the type of
donor cells, cell dose, time of administration after stroke, delivery route, and anesthetic. Treatment outcomes
were measured by infarct volume, behavioral tests, and molecular and cellular level results.
Conclusion:
Most of the preclinical studies reported statistically significant effects and very few adverse
reactions. Transplantation of NSPCs for ischemic stroke still needs to be optimized for several key factors.
A standardized treatment outcome assessment could ease the translation of evidence in clinical settings.
Publisher
Bentham Science Publishers Ltd.
Subject
General Medicine,Medicine (miscellaneous)
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献